ArticleReviews in cardiovascular medicine2026

Focus on Baseline LDL-C and Patient Risk, Not Drug Type: A Perspective on Alirocumab vs Evolocumab.

Pierre Sabouret et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.